139 related articles for article (PubMed ID: 29527515)
1. Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression.
Oehl K; Kresoja-Rakic J; Opitz I; Vrugt B; Weder W; Stahel R; Wild P; Felley-Bosco E
Front Oncol; 2018; 8():40. PubMed ID: 29527515
[TBL] [Abstract][Full Text] [Related]
2. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
3. Wnt/IL-1β/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5.
Milosevic V; Kopecka J; Salaroglio IC; Libener R; Napoli F; Izzo S; Orecchia S; Ananthanarayanan P; Bironzo P; Grosso F; Tabbò F; Comunanza V; Alexa-Stratulat T; Bussolino F; Righi L; Novello S; Scagliotti GV; Riganti C
Int J Cancer; 2020 Jan; 146(1):192-207. PubMed ID: 31107974
[TBL] [Abstract][Full Text] [Related]
4. Arachidonic acid drives adaptive responses to chemotherapy-induced stress in malignant mesothelioma.
Cioce M; Canino C; Pass H; Blandino G; Strano S; Fazio VM
J Exp Clin Cancer Res; 2021 Nov; 40(1):344. PubMed ID: 34727953
[TBL] [Abstract][Full Text] [Related]
5. SOCS-1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma.
Iwahori K; Serada S; Fujimoto M; Ripley B; Nomura S; Mizuguchi H; Shimada K; Takahashi T; Kawase I; Kishimoto T; Naka T
Int J Cancer; 2013 Jan; 132(2):459-71. PubMed ID: 22532243
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Characterization of Cisplatin and Pemetrexed Effects in Malignant Pleural Mesothelioma 3D Culture Phenotypes.
Papazoglou ED; Jagirdar RM; Kouliou OA; Pitaraki E; Hatzoglou C; Gourgoulianis KI; Zarogiannis SG
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569615
[TBL] [Abstract][Full Text] [Related]
7. SASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells.
Canino C; Mori F; Cambria A; Diamantini A; Germoni S; Alessandrini G; Borsellino G; Galati R; Battistini L; Blandino R; Facciolo F; Citro G; Strano S; Muti P; Blandino G; Cioce M
Oncogene; 2012 Jun; 31(26):3148-63. PubMed ID: 22020330
[TBL] [Abstract][Full Text] [Related]
8. Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed.
Hayashi H; Okamoto I; Ichikawa Y; Miyazaki M; Yoshioka H; Kunimasa K; Nakagawa K
Int J Clin Oncol; 2010 Oct; 15(5):497-9. PubMed ID: 20224880
[TBL] [Abstract][Full Text] [Related]
9. CD26 overexpression is associated with prolonged survival and enhanced chemosensitivity in malignant pleural mesothelioma.
Aoe K; Amatya VJ; Fujimoto N; Ohnuma K; Hosono O; Hiraki A; Fujii M; Yamada T; Dang NH; Takeshima Y; Inai K; Kishimoto T; Morimoto C
Clin Cancer Res; 2012 Mar; 18(5):1447-56. PubMed ID: 22261805
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
12. LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.
Scagliotti GV; Gaafar R; Nowak AK; Reck M; Tsao AS; van Meerbeeck J; Vogelzang NJ; Nakano T; von Wangenheim U; Velema D; Morsli N; Popat S
Clin Lung Cancer; 2017 Sep; 18(5):589-593. PubMed ID: 28690011
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
[TBL] [Abstract][Full Text] [Related]
14. Malignant pleural mesothelioma.
Chen SE; Pace MB
Am J Health Syst Pharm; 2012 Mar; 69(5):377-85. PubMed ID: 22345416
[TBL] [Abstract][Full Text] [Related]
15. Pleural mesothelioma side populations have a precursor phenotype.
Frei C; Opitz I; Soltermann A; Fischer B; Moura U; Rehrauer H; Weder W; Stahel R; Felley-Bosco E
Carcinogenesis; 2011 Sep; 32(9):1324-32. PubMed ID: 21729925
[TBL] [Abstract][Full Text] [Related]
16. Isolation of Chemoresistant Cell Subpopulations.
Canino C; Cioce M
Methods Mol Biol; 2016; 1379():139-50. PubMed ID: 26608297
[TBL] [Abstract][Full Text] [Related]
17. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
Boons CC; VAN Tulder MW; Burgers JA; Beckeringh JJ; Wagner C; Hugtenburg JG
Anticancer Res; 2013 Sep; 33(9):3553-61. PubMed ID: 24023280
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs dysregulation in human malignant pleural mesothelioma.
Balatti V; Maniero S; Ferracin M; Veronese A; Negrini M; Ferrocci G; Martini F; Tognon MG
J Thorac Oncol; 2011 May; 6(5):844-51. PubMed ID: 21358347
[TBL] [Abstract][Full Text] [Related]
19. Interaction and cross-resistance of cisplatin and pemetrexed in malignant pleural mesothelioma cell lines.
Kitazono-Saitoh M; Takiguchi Y; Kitazono S; Ashinuma H; Kitamura A; Tada Y; Kurosu K; Sakaida E; Sekine I; Tanabe N; Tagawa M; Tatsumi K
Oncol Rep; 2012 Jul; 28(1):33-40. PubMed ID: 22562354
[TBL] [Abstract][Full Text] [Related]
20. [Establishment and characterization of patient derived xenograft model of malignant peritoneal mesothelioma in nude mice].
Yang ZR; Lin YL; Zhang J; Ma R; Li Z; Jiang X; Zhao HY; Du XM; Li Y
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):162-167. PubMed ID: 32074730
[No Abstract] [Full Text] [Related]
[Next] [New Search]
